These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 28992881)

  • 21. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.
    Bai W; Wang YJ; Zhao Y; Qi XS; Yin ZX; He CY; Li RJ; Wu KC; Xia JL; Fan DM; Han GH
    J Dig Dis; 2013 Apr; 14(4):181-90. PubMed ID: 23324079
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
    Lee JM; Jang BK; Lee YJ; Choi WY; Choi SM; Chung WJ; Hwang JS; Kang KJ; Kim YH; Chauhan AK; Park SY; Tak WY; Kweon YO; Kim BS; Lee CH
    Clin Mol Hepatol; 2016 Mar; 22(1):160-7. PubMed ID: 27044767
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status.
    Kodama K; Kawaoka T; Aikata H; Uchikawa S; Inagaki Y; Hatooka M; Morio K; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Masaki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Chayama K
    J Gastroenterol Hepatol; 2018 Oct; 33(10):1780-1786. PubMed ID: 29645345
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination of transcatheter arterial chemoembolization and interrupted dosing sorafenib improves patient survival in early-intermediate stage hepatocellular carcinoma: A post hoc analysis of the START trial.
    Lee TY; Lin CC; Chen CY; Wang TE; Lo GH; Chang CS; Chao Y
    Medicine (Baltimore); 2017 Sep; 96(37):e7655. PubMed ID: 28906355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transcatheter arterial chemoembolization plus sorafenib versus transcatheter arterial chemoembolization alone to treat advanced hepatocellular carcinoma: a meta-analysis.
    Cai R; Song R; Pang P; Yan Y; Liao Y; Zhou C; Wang S; Zhou X; Wang H; Zhang H; Sun H; Ma H
    BMC Cancer; 2017 Nov; 17(1):714. PubMed ID: 29110700
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced therapeutic efficacy of combined use of sorafenib and transcatheter arterial chemoembolization for treatment of advanced hepatocellular carcinoma.
    Zhou L; Li J; Ai DL; Fu JL; Peng XM; Zhang LZ; Wang JY; Zhao Y; Yang B; Yu Q; Liu CZ; Wang HM
    Jpn J Clin Oncol; 2014 Aug; 44(8):711-7. PubMed ID: 24855686
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization.
    Hatooka M; Kawaoka T; Aikata H; Morio K; Kobayashi T; Hiramatsu A; Imamura M; Kawakami Y; Murakami E; Waki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Chayama K
    Anticancer Res; 2016 Jul; 36(7):3523-9. PubMed ID: 27354618
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interim analysis of START: Study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial.
    Chung YH; Han G; Yoon JH; Yang J; Wang J; Shao GL; Kim BI; Lee TY; Chao Y
    Int J Cancer; 2013 May; 132(10):2448-58. PubMed ID: 23129123
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sorafenib enhances effects of transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis.
    Fu QH; Zhang Q; Bai XL; Hu QD; Su W; Chen YW; Su RG; Liang TB
    J Cancer Res Clin Oncol; 2014 Aug; 140(8):1429-40. PubMed ID: 24770582
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization plus sorafenib.
    Meng XC; Chen BH; Huang JJ; Huang WS; Cai MY; Zhou JW; Guo YJ; Zhu KS
    World J Gastroenterol; 2018 Jan; 24(4):484-493. PubMed ID: 29398869
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Validation of the criteria of transcatheter arterial chemoembolization failure or refractoriness in patients with advanced hepatocellular carcinoma proposed by the LCSGJ.
    Arizumi T; Ueshima K; Chishina H; Kono M; Takita M; Kitai S; Inoue T; Yada N; Hagiwara S; Minami Y; Sakurai T; Nishida N; Kudo M
    Oncology; 2014; 87 Suppl 1():32-6. PubMed ID: 25427731
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of sorafenib as a first-line treatment for advanced hepatocellular carcinoma.
    Zhang P; Yang Y; Wen F; He X; Tang R; Du Z; Zhou J; Zhang J; Li Q
    Eur J Gastroenterol Hepatol; 2015 Jul; 27(7):853-9. PubMed ID: 25919775
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of Potential Predictors of Prognosis and Sorafenib-Associated Survival Benefits in Patients with Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization.
    He K; Yang Z; Liu X; Yang Y; Song W; Wang S; Chen Y
    Curr Oncol; 2022 Dec; 30(1):476-491. PubMed ID: 36661687
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transarterial chemoembolization and sorafenib in hepatocellular carcinoma.
    Cabibbo G; Tremosini S; Galati G; Mazza G; Gadaleta-Caldarola G; Lombardi G; Antonucci M; Sacco R
    Expert Rev Anticancer Ther; 2014 Jul; 14(7):831-45. PubMed ID: 24850249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survival benefit of transarterial chemoembolization in patients with metastatic hepatocellular carcinoma: a single center experience.
    Bettinger D; Spode R; Glaser N; Buettner N; Boettler T; Neumann-Haefelin C; Brunner TB; Gkika E; Maruschke L; Thimme R; Schultheiss M
    BMC Gastroenterol; 2017 Aug; 17(1):98. PubMed ID: 28797231
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination of TACE and Sorafenib Improves Outcomes in BCLC Stages B/C of Hepatocellular Carcinoma: A Single Centre Experience.
    Varghese J; Kedarisetty C; Venkataraman J; Srinivasan V; Deepashree T; Uthappa M; Ilankumaran K; Govil S; Reddy M; Rela M
    Ann Hepatol; 2017; 16(2):247-254. PubMed ID: 28233748
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The feasibility of combined transcatheter arterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma.
    Cho JY; Paik YH; Park HC; Yu JI; Sohn W; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    Liver Int; 2014 May; 34(5):795-801. PubMed ID: 24350564
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Successful treatment of metastatic hepatocellular carcinoma with sorafenib combined with transcatheter arterial chemoembolization/hepatic arterial infusion chemotherapy].
    Watanabe Y; Nakaba H; Taniguchi E; Kikkawa H; Tamagawa H; Sasaki M; Kitayama T; Doi Y; Oguchi Y
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):2110-2. PubMed ID: 25731439
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sorafenib combined with TACE in advanced primary hepatocellular carcinoma.
    Cui HZ; Dai GH; Shi Y; Chen L
    Hepatogastroenterology; 2013; 60(122):305-10. PubMed ID: 23574656
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sorafenib combined with transarterial chemoembolization in patients with hepatocellular carcinoma: a meta-analysis and systematic review.
    Wang G; Liu Y; Zhou SF; Qiu P; Xu L; Wen P; Wen J; Xiao X
    Hepatol Int; 2016 May; 10(3):501-10. PubMed ID: 26856326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.